---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-039020"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:29:11.487212+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics secures $4.0M from warrant exercise; GTx-104 PDUFA date set for April 23, 2026

## Summary
- Secured $4.0M via exercise of 1,345,464 common warrants at $3.003/share from September 2023 private placement.
- Remaining 1,190,927 warrants from the same placement expired after FDA accepted GTx-104 NDA for review.
- FDA set PDUFA target date of April 23, 2026 for GTx-104 NDA for aneurysmal subarachnoid hemorrhage (aSAH).
- GTx-104 is a novel injectable nimodipine formulation for I.V. infusion in aSAH patients.

## SEC filing metadata
- accession: 0001140361-25-039020
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036125039020/0001140361-25-039020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036125039020/ef20057547_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-039020
- JSON: https://secwatch.observer/filing/0001140361-25-039020.json
- Plain text: https://secwatch.observer/filing/0001140361-25-039020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.